InferRead CT Stroke.AI

by Infervision Medical Technology Co.  · Based in China → — With A.I., We improve human life.
Emergency Medicine Neurology Radiology

Regulatory Status Disclosed

Overview

InferRead CT Stroke.AI is an AI-powered software developed by Infervision Medical Technology Co. that leverages deep learning algorithms to assist hospitals and radiologists in prioritizing head CT scans. Its primary function is to flag suspected cases of intracranial hemorrhage (ICH) by analyzing non-enhanced head CT images. This radiological computer-aided triage and notification software operates alongside standard radiology workflows, highlighting potential emergency cases on a worklist to facilitate faster triage without altering original images or removing cases from the reading queue. The system aims to empower doctors with higher efficiency and benefit patients with better diagnosis and outcomes. Infervision, established in 2016, is a leading AI medical technology company focused on improving multi-disciplinary services and operations with AI across disease screening and diagnosis, patient treatment and management, and research and development.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered intracranial hemorrhage (ICH) detection
  • Head CT scan prioritization
  • Deep learning algorithm for image analysis
  • Workflow triage and notification
  • ASPECT score calculation (for related product, but mentioned in context of stroke AI)
  • Dynamic evaluation of active bleeding (for related product, but mentioned in context of stroke AI)
  • Midline shift detection (for related product, but mentioned in context of stroke AI)
  • Operates alongside standard radiology workflows
  • Does not alter original images or remove cases from queue
  • Processes DICOM image series

Use Cases

  • Expediting triage of suspected intracranial hemorrhage cases
  • Improving efficiency in radiology workflow
  • Assisting clinicians in faster detection of brain hemorrhages
  • Prioritizing emergency head CT scans
  • Supporting diagnostic decisions in stroke emergency treatments

What Physicians Need to Know

Stroke Detection Speed
Average time to notification for suspected intracranial hemorrhage is 1.07 minutes, significantly faster than the standard of care time-to-opening exam of over 75 minutes.
Brain CT Analysis
InferRead CT Stroke.AI analyzes non-enhanced head CT images using deep learning algorithms to detect suspected intracranial hemorrhage (ICH). It can accurately locate bleeding areas, estimate bleeding volume, and detect potential cerebral palsy. The system also performs dynamic assessment and risk assessment of active bleeding. For ischemic stroke, it offers intelligent CT scoring and intelligent CTP quantitative analysis, and intelligent CTA assisted diagnosis as part of a broader solution.
Large Vessel Occlusion Detection
While primarily focused on ICH triage, InferRead CT Stroke is part of a broader 'one-stop AI solution' that includes an AI quantitative analysis module for ischemic stroke and an intelligent CTA assisted diagnosis system, which can be instrumental in identifying large vessel occlusions.
Triage Prioritization Speed
The software prioritizes head CT scans by flagging suspected intracranial hemorrhage cases and highlighting potential emergency cases on a worklist, assisting clinicians in faster triage. It operates in parallel with standard radiology workflows.
ASPECTS Score Automation
InferRead CT Stroke can automatically calculate the Alberta Stroke Program Early CT Score (ASPECTS), which aids in improving the consistency of ischemic assessment, treatment plan selection, and prognosis assessment.
Mobile Notification System
The AI algorithm can send real-time notifications of positive findings to mobile phones or hospital text page systems, enhancing the ability to alert and attend to patients promptly.
Physician Tip

InferRead CT Stroke.AI serves as a valuable triage and notification tool, significantly accelerating the identification of suspected intracranial hemorrhage on non-enhanced head CT scans. Physicians should utilize this tool to prioritize urgent cases, enabling faster intervention and potentially improving patient outcomes. It is crucial to remember that the AI is a triage assistant, and final diagnostic decisions must always be made by a qualified physician after reviewing the full images and integrating all available clinical information. The automated ASPECTS scoring can provide a standardized assessment, but clinical judgment remains paramount.

The InferRead CT Stroke.AI software is designed for seamless integration into existing hospital radiology workflows. It operates on an onsite hospital server with client workstations and is compatible with DICOM 3.0 CT images. It can function as a standalone desktop application and integrates with PACS infrastructure to receive and process DICOM series.

Details

Category Neurology AI, Radiology & Imaging AI, Triage & ER/ICU AI
Pricing Unknown
DeploymentOn-premise (onsite hospital server with client workstations)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

InferRead CT Stroke.AI received FDA 510(k) clearance (K211179) on August 12, 2021, as radiological computer aided triage and notification software for use in the analysis of non-enhanced head CT images to flag suspected positive findings of intracranial hemorrhage (ICH).

Integrations
EHR Not specified
Specialties Emergency Medicine, Neurology, Radiology

What the Web Says

InferRead CT Stroke.AI is an AI-powered software designed to assist physicians in the rapid and accurate diagnosis and triage of stroke patients, particularly for intracranial hemorrhage (ICH) and large vessel occlusions (LVOs). It has received regulatory approvals from both China's NMPA and the U.S. FDA, as well as European MDR CE and UKCA certifications. The system aims to reduce critical delays in stroke care by automating the analysis of CT scans, thereby improving treatment times and potentially patient outcomes.

Overall: Mixed

Strengths

  • Rapid analysis of CT scans, reducing diagnosis and notification times significantly (e.g., 1-6 minutes for AI vs. 15-60 minutes for traditional methods).
  • High sensitivity and specificity for detecting intracranial hemorrhages (ICH) and large vessel occlusions (LVOs), often matching or exceeding human radiologist performance in controlled studies.
  • Aids in personalized and timely interventions, improving overall management of stroke patients.
  • Can help less experienced doctors interpret acute stroke CT scans, improving correlation with reference standards.
  • Potentially reduces healthcare costs and offers a scalable solution for routine stroke care, especially in resource-limited settings.
  • Integrates into existing clinical workflows, providing imaging-assisted diagnosis for multiple body areas.

Limitations

  • Performance can drop significantly for medium vessel occlusions and posterior circulation strokes.
  • May produce false positives, particularly for intracranial hemorrhage detection at the falx or dural calcifications.
  • Struggled with hemorrhagic transformation detection in some cases, missing early bleeding that radiologists caught.
  • AI systems are not standalone rule-out tools for certain hemorrhage subtypes like epidural or subarachnoid hemorrhage, requiring radiologist review for AI-negative studies when suspicion is high.
  • The technology is still evolving, and some studies highlight a gap between process improvements (speed) and statistically significant differences in clinical outcomes (mRS, mortality).
  • Requires human oversight for final diagnostic decisions and cannot fully replace radiologists due to medicolegal reasons and the need for comprehensive pathology assessment.

Based on reviews from: PMC, BioWorld, Infervision, Articsledge, Reddit, MDPI, MedTrainHub, Trakterm, Medical News Today, Skywork, AuntMinnie, G2

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate InferRead CT Stroke.AI

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

BioWorld
Infervision receives nod for AI-powered CT reader in China
Infervision Medical Technology Co. Ltd. received NMPA approval in China for its InferRead CT Stroke, a radiological computer-assisted triage and notification software device for brain hemorrhage. This product, along with InferRead CT Stroke.AI, relies on AI to automatically process and analyze head CT images to identify brain hemorrhage abnormalities and triage patients.
2022-07
Qiming Venture Partners
Qiming Venture Partners Monthly Newsletter | August
Infervision received FDA clearance for its u201cInferRead CT Stroke.AIu201d product in August 2021. This AI-powered tool utilizes deep learning to improve the efficiency of stroke diagnosis, enabling earlier diagnosis and treatment.
2021-09
Blackford Analysis
Partner Highlights: January 2022 - Blackford Analysis
InferRead CT Stroke.AI has received FDA clearance for use in the US, expanding Infervision's portfolio of AI products alongside their CT Lung AI. Infervision is also contributing to efforts to combat tuberculosis with AI-powered X-ray detection solutions.
2022-02
Moomoo
New stock news | hypothetical Medical delivery form HKEx, the only AI medical technology company in the world that has been certified by the top four. - Moomoo
Infervision Medical Technology Co., Ltd. (Infervision Medical Technology Co., Ltd.) submitted a listing application to the main board of the HKEx, highlighting that its InferRead CT Stroke.AI product received US FDA certification in August 2021. This made Infervision the first Chinese AI medical technology company with two FDA certifications.
2021-08
Infervision
Stroke AI won the second certificate of FDA, it is speculated that ...
Infervision's medical stroke AI product, 'InferRead CT Stroke.AI', has been certified by the US Food and Drug Administration (FDA). This marks the product's second FDA certification, enabling its official market access in the United States.
unknown
British Journal of Radiology
Artificial intelligence in neuroradiology: a review of Food and Drug Administration-regulated algorithms | British Journal of Radiology | Oxford Academic
InferRead CT Stroke.AI, developed by Beijing Infervision Med Tech (China), is listed as an FDA-cleared computer-aided triage (CADt) algorithm for the detection and flagging of intracranial hemorrhage (ICH) on CT scans, with a clearance date of August 12, 2021.
2026-05
Stroke: Journal of the American Heart Association
Accuracy of Automated Computer-Aided Diagnosis for Stroke Imaging: A Critical Evaluation of Current Evidence
InferRead CT Stroke.AI is identified as an AI software that provides ASPECTS (Alberta Stroke Program Early CT Score) and detects hemorrhage on CT scans, with FDA classification as Class IIa. The article discusses the potential of AI in improving stroke diagnosis but also highlights challenges in clinical implementation.
2022-04
Cureus (via PMC)
Revolutionizing Acute Stroke Care: A Review of Food and Drug Administration-Approved Software as Medical Devices for Stroke Triage - PMC
InferRead CT Stroke.AI from China is an FDA-approved software as a medical device for stroke triage, specifically for intracranial hemorrhage (ICH) on NCCT head scans, demonstrating a sensitivity of 91.60% and specificity of 92.2% with a processing time of 1.07 minutes.
2024-11

Videos

Product demos, reviews, and walkthroughs for InferRead CT Stroke.AI.

View all on YouTube

Frequently Asked Questions

InferRead CT Stroke.AI integrates by analyzing non-enhanced head CT images on an onsite hospital server with client workstations. It flags suspected intracranial hemorrhage (ICH) cases on a worklist for prioritization, assisting radiologists in workflow triage without altering original images or removing cases from the reading queue.
InferRead CT Stroke.AI has received FDA approval in the U.S. and NMPA approval in China as a Class II and Class III medical device, respectively. While specific HIPAA/GDPR details for this product are not explicitly stated, Infervision generally emphasizes robust cybersecurity infrastructure and compliance with strict data protection standards for its solutions.
InferRead CT Stroke.AI demonstrated a sensitivity of 91.6% and specificity of 92.2% for intracranial hemorrhage detection, with an average notification time of 1.07 minutes. It is one of several FDA-approved AI solutions, alongside competitors like Viz.ai and RapidAI, which also report high accuracy and fast processing for stroke triage. Direct, comprehensive comparisons across all features and diverse datasets are often limited by proprietary software.
Specific pricing models for InferRead CT Stroke.AI are not publicly disclosed in the search results. However, Infervision generally offers its systems under various pricing models to facilitate acquisition, which typically include licensing fees, implementation costs, and ongoing support. These models aim to enhance efficiency and improve patient outcomes.
InferRead CT Stroke.AI is a triage and notification tool, not a standalone diagnostic device, and its results must be used with other patient information and professional judgment. Algorithm limitations, image quality, and scan parameters can affect accuracy, potentially leading to false positives or negatives. Clinicians are responsible for reviewing all images according to the standard of care.
Clinical testing on 369 non-contrast brain CT scans showed a sensitivity of 91.6% and specificity of 92.2% for intracranial hemorrhage detection. The system significantly reduced the average time to notification to 1.07 minutes, compared to over 75 minutes for standard of care, demonstrating improved workflow efficiency and potential for faster diagnosis.
While specific details for InferRead CT Stroke.AI are not explicitly stated, Infervision generally provides user operation training services for its products. Software installation, upgrades, and uninstallation are typically handled by Infervision personnel or approved technicians to ensure proper functionality and data security.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

More from Infervision Medical Technology

InferRead Lung CT.AI
Infervision Medical Technology Co.
Oncology AI
InferRead Lung CT.AI by Infervision is an AI-powered tool designed to assist radiologists in detecting, quantifying, and classifying pulmonary nodules from chest CT scans, enhancing diagnostic accuracy and efficiency for lung cancer screening and diagnosis.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.